Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.33
13
|
Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ONCO3 stock under the Base Case scenario is 12.17 BRL. Compared to the current market price of 3.33 BRL, Oncoclinicas do Brasil Servicos Medicos SA is Undervalued by 73%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Oncoclinicas do Brasil Servicos Medicos SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ONCO3 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Oncoclinicas do Brasil Servicos Medicos SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Oncoclinicas do Brasil Servicos Medicos SA
Balance Sheet Decomposition
Oncoclinicas do Brasil Servicos Medicos SA
Current Assets | 5B |
Cash & Short-Term Investments | 2.2B |
Receivables | 2.4B |
Other Current Assets | 382.8m |
Non-Current Assets | 7.3B |
Long-Term Investments | 127.2m |
PP&E | 1.4B |
Intangibles | 4.5B |
Other Non-Current Assets | 1.3B |
Current Liabilities | 2.5B |
Accounts Payable | 1.1B |
Accrued Liabilities | 385m |
Other Current Liabilities | 1.1B |
Non-Current Liabilities | 5.9B |
Long-Term Debt | 4.8B |
Other Non-Current Liabilities | 1.1B |
Earnings Waterfall
Oncoclinicas do Brasil Servicos Medicos SA
Revenue
|
6.1B
BRL
|
Cost of Revenue
|
-4.1B
BRL
|
Gross Profit
|
2B
BRL
|
Operating Expenses
|
-1.3B
BRL
|
Operating Income
|
756.4m
BRL
|
Other Expenses
|
-684m
BRL
|
Net Income
|
72.4m
BRL
|
Free Cash Flow Analysis
Oncoclinicas do Brasil Servicos Medicos SA
BRL | |
Free Cash Flow | BRL |
In Q2 2024, Oncoclínicas delivered 16% revenue growth, reaching BRL 1.7 billion, driven by increased treatment volumes and higher average ticket prices. The company’s EBITDA improved to BRL 300 million, with a margin of 19.2%, up 270 basis points sequentially due to disciplined cost control. Net income grew 16% from the previous quarter to BRL 300 million. Despite challenges such as floods in Rio Grande do Sul, operational efficiency improved, cash operating expenses reduced, and leverage decreased to 2.5x EBITDA. The oncology market's annual growth of 13% positions Oncoclínicas for continued market share gains.
What is Earnings Call?
ONCO3 Profitability Score
Profitability Due Diligence
Oncoclinicas do Brasil Servicos Medicos SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Oncoclinicas do Brasil Servicos Medicos SA's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
ONCO3 Solvency Score
Solvency Due Diligence
Oncoclinicas do Brasil Servicos Medicos SA's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Oncoclinicas do Brasil Servicos Medicos SA's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ONCO3 Price Targets Summary
Oncoclinicas do Brasil Servicos Medicos SA
According to Wall Street analysts, the average 1-year price target for ONCO3 is 8.47 BRL with a low forecast of 5.76 BRL and a high forecast of 13.65 BRL.
Dividends
Current shareholder yield for ONCO3 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Oncoclínicas do Brasil Serviços Médicos SA operates as a holding company, which engages in oncology clinics through the health care segment. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2021-08-10. The firm provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The firm holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Contact
IPO
Employees
Officers
The intrinsic value of one ONCO3 stock under the Base Case scenario is 12.17 BRL.
Compared to the current market price of 3.33 BRL, Oncoclinicas do Brasil Servicos Medicos SA is Undervalued by 73%.